Roche: Chugai Receives Orphan Drug Designation for TECENTRIQ in Small Cell Lung Cancer and for Entrectinib in NTRK Fusion-positive Solid Tumors Donnerstag, 06. Dezember 2018 - 17:56

Chugai Receives Orphan Drug Designation for TECENTRIQ in Small Cell Lung Cancer and for Entrectinib in NTRK Fusion-positive Solid Tumors

Dear Investor,

Please find attached a press release by Chugai:
https://www.roche.com/181206_IR_Chugai_eODD_entrectinib_Tecentriq.pdf

Do not hesitate to contact us for any further questions.

With best regards,

Roche Investor Relations
Dr. Karl Mahler Phone: +41 61 68-78503 e-mail: karl.mahler@roche.com	Jon Kaspar Bayard Phone: +41 61 68-83894 e-mail: jon_kaspar.bayard@roche.com
Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com	Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com	Dr. Gerard Tobin Phone: +41 61 68-72942 e-mail: gerard.tobin@roche.com

Investor Relations North America
Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com	Dr. Lisa Tuomi Phone: +1 650 467 8737 e-mail: tuomi.lisa@gene.com